Sujith Samarasinghe
Overview
Explore the profile of Sujith Samarasinghe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1994
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Clesham K, Walf-Vorderwulbecke V, Gasparoli L, Virely C, Cantilena S, Tsakaneli A, et al.
Leukemia
. 2022 Apr;
36(6):1541-1549.
PMID: 35368048
A significant proportion of patients suffering from acute myeloid leukemia (AML) cannot be cured by conventional chemotherapy, relapsed disease being a common problem. Molecular targeting of essential oncogenic mediators is...
12.
Nielsen R, Wolthers B, Helenius M, Albertsen B, Clemmensen L, Nielsen K, et al.
J Pediatr Hematol Oncol
. 2022 Feb;
44(3):e628-e636.
PMID: 35226426
Asparaginase-associated pancreatitis (AAP) frequently affects children treated for acute lymphoblastic leukemia (ALL) causing severe acute and persisting complications. Known risk factors such as asparaginase dosing, older age and single nucleotide...
13.
Gabelli M, Marks D, Sharplin K, Lazareva A, Mullanfiroze K, Farish S, et al.
Br J Haematol
. 2021 Jul;
195(5):805-811.
PMID: 34322864
No abstract available.
14.
Green K, Tandon S, Ahmed M, Toscano W, OConnor D, Ancliff P, et al.
Leuk Lymphoma
. 2020 Nov;
62(3):688-695.
PMID: 33225799
Congenital Acute Myeloid leukemia (CAML) is a rare leukemia diagnosed within the first 28 days of life. Dismal survival rates of approximately 25% at two years from diagnosis have not...
15.
Leong S, Inglott S, Papaleonidopoulou F, Orfinada K, Ancliff P, Bartram J, et al.
Blood Adv
. 2020 Oct;
4(19):4665-4668.
PMID: 33002130
No abstract available.
16.
ARHGEF4 Regulates an Essential Oncogenic Program in t(12;21)-Associated Acute Lymphoblastic Leukemia
Virely C, Gasparoli L, Mangolini M, Clesham K, Inglott S, Edwards D, et al.
Hemasphere
. 2020 Sep;
4(5):e467.
PMID: 32984770
No abstract available.
17.
Moorman A, Schwab C, Winterman E, Hancock J, Castleton A, Cummins M, et al.
Br J Haematol
. 2020 Sep;
191(5):844-851.
PMID: 32926422
Patients with an ABL-class fusion have a high risk of relapse on standard chemotherapy but are sensitive to tyrosine kinase inhibitors (TKI). In UKALL2011, we screened patients with post-induction MRD...
18.
Orf K, Rogosic S, Dexter D, Ancliff P, Badle S, Brierley J, et al.
Br J Haematol
. 2020 Jul;
190(5):e274-e276.
PMID: 32652563
No abstract available.
19.
Prunotto G, Offor U, Samarasinghe S, Wynn R, Vora A, Carpenter B, et al.
J Allergy Clin Immunol
. 2020 May;
146(2):447-450.
PMID: 32371070
No abstract available.
20.
Enshaei A, OConnor D, Bartram J, Hancock J, Harrison C, Hough R, et al.
Blood
. 2020 Apr;
135(17):1438-1446.
PMID: 32315382
Risk stratification is essential for the delivery of optimal treatment in childhood acute lymphoblastic leukemia. However, current risk stratification algorithms dichotomize variables and apply risk factors independently, which may incorrectly...